- Group 3: 0.6 mg DSP with 50 mM PL (50 µL) Randomization will be performed centrally. Stratification in the enrolled patients will be done by RVO type (BRVO or CRVO) for meaningful data analyses. Only the patient will be masked. The Investigator as well as the administration staff will be aware of the dose of the study medication. The safety and efficacy outcomes will be assessed for up to about 12 months.